Hamed, M., Bahaaeldin, A., Mostafa, B. (2022). Anti-Glutamic Acid Decarboxylase 65 as a Predictor of Progressive Insulin Deficiency in Type 2 Diabetes. Suez Canal University Medical Journal, 25(2), 12-18. doi: 10.21608/scumj.2022.223253
Mohammed Hamed; Ahmed M. Bahaaeldin; Bassem M. Mostafa. "Anti-Glutamic Acid Decarboxylase 65 as a Predictor of Progressive Insulin Deficiency in Type 2 Diabetes". Suez Canal University Medical Journal, 25, 2, 2022, 12-18. doi: 10.21608/scumj.2022.223253
Hamed, M., Bahaaeldin, A., Mostafa, B. (2022). 'Anti-Glutamic Acid Decarboxylase 65 as a Predictor of Progressive Insulin Deficiency in Type 2 Diabetes', Suez Canal University Medical Journal, 25(2), pp. 12-18. doi: 10.21608/scumj.2022.223253
Hamed, M., Bahaaeldin, A., Mostafa, B. Anti-Glutamic Acid Decarboxylase 65 as a Predictor of Progressive Insulin Deficiency in Type 2 Diabetes. Suez Canal University Medical Journal, 2022; 25(2): 12-18. doi: 10.21608/scumj.2022.223253
Anti-Glutamic Acid Decarboxylase 65 as a Predictor of Progressive Insulin Deficiency in Type 2 Diabetes
Department of Internal Medicine and Endocrinology, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Abstract
Background: For type 2 diabetes, there are few usual highly specific indicators, though the presence of risk factors such as obesity indicates the likelihood of developing type 2 diabetes. Aim:To assess the anti-glutamic acid decarboxylase 65 (anti-GAD65) level in type 2 Egyptian Diabetic patients and if it could be used as a marker for progression to insulin deficiency and treatment with insulin. Patients and Methods: a cross-sectional study was conducted on 100 patients with type 2 diabetes mellitus (T2DM) who were divided into group1 as 50 patients on oral antidiabetic drugs (OADs) for more than 5 years and another 50 patients as group 2 on insulin after being previously on OADs. Patients with type 1 diabetes, T2DM associated with any auto-immune disease, T2DM with chronic kidney disease (CKD), or chronic liver disease (CLD) were excluded. Full history taking, clinical examination, and liver and kidney functions were performed in addition to FBS, HbA1c, C- peptide, and anti-glutamic acid decarboxylase 65 (anti- GAD65) antibody. Results: statistically significant positive correlation between Anti-GAD 65 levels and age (r=0.262, P-value=0.008) and negative correlation between Anti-GAD 65 levels and fasting C-peptide (r=-0.27, P-value=0.006) were found. Conclusion:Anti-glutamic acid decarboxylase antibody 65 is more positive in the OAD group than in the insulin group but it is not p-value significant. Anti-glutamic acid decarboxylase antibodies are positively correlated with age also,it is negatively correlated with fasting C-peptide. So, it can be used as a marker for pancreatic reserve and progressive Insulin Deficiency in type 2 Egyptian patients.
View on SCiNiTO
Top